Y-mAbs Therapeutics, Inc. Profile Avatar - Palmy Investing

Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal anti…

Biotechnology
US, New York [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of YMAB's Analysis
CIK: 1722964 CUSIP: 984241109 ISIN: US9842411095 LEI: - UEI: -
Secondary Listings
YMAB has no secondary listings inside our databases.